Introduction: Carboplatin-Etoposide is a first-line option for patients (pts) with advanced EP-PD-NEC. Data from randomised trials are lacking
Aim(s): The aim was to provide real-life activity/efficacy/safety data on CB-ET in this setting
Materials and methods: Records of pts with advanced EP-PD-NEC (06/09-04/17) treated with CB-ET were retrospectively reviewed
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Melissa Frizziero
To read results and conclusion, please login ...
Further abstracts you may be interested in